Tailoring caplacizumab administration using ADAMTS13 activity for immune-mediated thrombotic thrombocytopenic purpura.

Blood Vessel Thromb Hemost · 2024 · PMC12320409 · PMID 40766810

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

showed a trendP = .1so close (0.05 < p ≤ 0.1)

Interestingly, when measured twice weekly during acute treatment, patients receiving caplacizumab showed a trend toward a shorter time to ADAMTS13 activity recovery >30% relative to the historical non-caplacizumab cohort (median, 9 days vs 18 days; P = .1).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.